GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ProPhase Labs Inc (NAS:PRPH) » Definitions » Earnings Yield (Joel Greenblatt) %

ProPhase Labs (ProPhase Labs) Earnings Yield (Joel Greenblatt) % : -21.93% (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is ProPhase Labs Earnings Yield (Joel Greenblatt) %?

ProPhase Labs's Enterprise Value for the quarter that ended in Dec. 2023 was $98.21 Mil. ProPhase Labs's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-21.53 Mil. ProPhase Labs's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was -21.93%.

The historical rank and industry rank for ProPhase Labs's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

PRPH' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1206.14   Med: -6.77   Max: 236.63
Current: -19.92

During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of ProPhase Labs was 236.63%. The lowest was -1206.14%. And the median was -6.77%.

PRPH's Earnings Yield (Joel Greenblatt) % is ranked worse than
71.79% of 234 companies
in the Medical Diagnostics & Research industry
Industry Median: -2.42 vs PRPH: -19.92

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. ProPhase Labs's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


ProPhase Labs Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for ProPhase Labs's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProPhase Labs Earnings Yield (Joel Greenblatt) % Chart

ProPhase Labs Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.49 -1.79 5.94 16.26 -21.93

ProPhase Labs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.26 6.54 -5.34 -16.31 -21.93

Competitive Comparison of ProPhase Labs's Earnings Yield (Joel Greenblatt) %

For the Diagnostics & Research subindustry, ProPhase Labs's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProPhase Labs's Earnings Yield (Joel Greenblatt) % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where ProPhase Labs's Earnings Yield (Joel Greenblatt) % falls into.



ProPhase Labs Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

ProPhase Labss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-21.525/98.2074
=-21.92 %

ProPhase Labs's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.53 Mil.



ProPhase Labs  (NAS:PRPH) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


ProPhase Labs Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of ProPhase Labs's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


ProPhase Labs (ProPhase Labs) Business Description

Traded in Other Exchanges
N/A
Address
711 Stewart Avenue, Suite 200, Garden City, NY, USA, 11530
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
Executives
Morse Robert A. Jr. officer: Controller 711 STEWART AVENUE, SUITE 200, GARDEN CITY NY 11530
Billy Joe White officer: Chief Financial Officer 191 OTTO ST., PORT TOWNSEND WA 98368
Jason Michael Barr director 902 BROADWAY, 15TH FLOOR, NEW YORK NY 10010
Louis Md Gleckel 10 percent owner C/O PROHEALTH CARE ASSOCIATES LLP, 2800 METRUS AVE, LAKE SUCCESS NY 11042
Ted William Karkus 10 percent owner 188 HEWLETT NECK ROAD, WOODMERE NY 11598
Warren Hirsch director 621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Monica L. Brady officer: Chief Accounting Officer 621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Cuddihy Robert V Jr officer: Chief Operating Officer PARKER DURYEE ET AL, 529 FIFTH AVE 8TH FL, NEW YORK NY 10017
Braden Michael Leonard 10 percent owner 156 S. FIRST STREET, ZIONSVILLE IN 46077
Mark S Leventhal 10 percent owner THE BEACON COMPANIES, 50 FEDERAL STREET, BOSTON MA 02468
Mark Shawn Frank director 104 WHISPER WOOD COURT, WRIGHTSTOWN PA 18940
James T Mccubbin director
Mark A. Burnett 10 percent owner 40 HEMLOCK DRIVE, ROSLYN NY 11576
Guy J Quigley director, 10 percent owner, officer: Chairman, President, CEO C/O THE QUIGLEY CORP KELLS BUILDINGS, 621 SHADY RETREAT RD P O BOX 1349, DOYLESTOWN PA 18901
John Deshazo 10 percent owner 17 WOLCOTT COURT, BOSTON MA 02136

ProPhase Labs (ProPhase Labs) Headlines

From GuruFocus

ProPhase Labs Announces Collaboration with Dana-Farber Cancer Institute

By Value_Insider Value_Insider 11-08-2022